65 related articles for article (PubMed ID: 22974332)
1. Dosimetry study of [I-131] and [I-125]- meta-iodobenz guanidine in a simulating model for neuroblastoma metastasis.
Roa WH; Yaremko B; McEwan A; Amanie J; Yee D; Cho J; McQuarrie S; Riauka T; Sloboda R; Wiebe L; Loebenberg R; Janicki C
Technol Cancer Res Treat; 2013 Feb; 12(1):79-90. PubMed ID: 22974332
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
4. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
[TBL] [Abstract][Full Text] [Related]
5. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
6. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
[TBL] [Abstract][Full Text] [Related]
7. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
8. Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for
Seo Y; Huh Y; Huang SY; Hernandez-Pampaloni JM; Hawkins RA; Gustafson WC; Vo KT; Matthay KK
Med Phys; 2019 May; 46(5):2477-2486. PubMed ID: 30761545
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and therapy of neuroectodermal tumors].
Adolph J; Kimmig B
Radiologe; 1989 Jan; 29(1):32-42. PubMed ID: 2537501
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.
Buckley SE; Saran FH; Gaze MN; Chittenden S; Partridge M; Lancaster D; Pearson A; Flux GD
Cancer Biother Radiopharm; 2007 Feb; 22(1):105-12. PubMed ID: 17627418
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
12. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
13. [Initial experiences in the treatment of children with metastatic and recurrent neuroblastoma using meta-iodobenzylguanidine].
Klingebiel T; Feine U; Niethammer D; Müller-Schauenburg W; Schwabe D; Maul FD; Gerein V; Fischer M; Gahr M; Kraz K
Klin Padiatr; 1986; 198(3):230-6. PubMed ID: 3723987
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the dicentric chromosome assay as a biodosimetry tool for more personalized medicine in a case of a high risk neuroblastoma
Chimeno JM; Sebastià N; Torres-Espallardo I; Balaguer J; Candela-Juan C; Loaiza JL; Adria M; Ibanez-Rosello B; Cañete A; Martí-Bonmatí L; Montoro A
Int J Radiat Biol; 2019 Mar; 95(3):314-320. PubMed ID: 30496023
[TBL] [Abstract][Full Text] [Related]
15. Optimum combination of targeted 131I and total body irradiation for treatment of disseminated cancer.
Amin AE; Wheldon TE; O'Donoghue JA; Gaze MN; Barrett A
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):713-21. PubMed ID: 7790258
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine.
Montaldo PG; Carbone R; Cornaglia Ferraris P; Ponzoni M
Cytotechnology; 1993; 11 Suppl 1():S140-3. PubMed ID: 7763744
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.
Matthay KK; Huberty JP; Hattner RS; Ablin AR; Engelstad BL; Zoger S; Hasegawa BH; Price D
J Nucl Biol Med (1991); 1991; 35(4):244-7. PubMed ID: 1823827
[TBL] [Abstract][Full Text] [Related]
18. [Internal radiation therapy for malignant neoplasm].
Yokoyama K; Kinuya S; Tonami N
Gan To Kagaku Ryoho; 1999 May; 26(6):768-74. PubMed ID: 10410145
[TBL] [Abstract][Full Text] [Related]
19. [131(I)-meta-iodobenzylguanidine treatment of 32 children with therapy-refractory neuroblastoma].
Berthold F; Feine U; Fischer M; Gerein V; Klingebiel T; Maul FD; Waters W; Wehinger H; Treuner J
Klin Padiatr; 1988; 200(3):226-9. PubMed ID: 3062260
[TBL] [Abstract][Full Text] [Related]
20. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
